RT Journal Article SR Electronic T1 Binding Characteristics of the New-Generation Tau PET Tracer [18F] -APN-1607 in Progressive Supranuclear Palsy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 461 OP 461 VO 61 IS supplement 1 A1 Ling Li A1 Jiaying Lu A1 Ming Li A1 Sun Yimin A1 Xiuming Li A1 Yihui Guan A1 Jian Wang A1 Chuantao Zuo YR 2020 UL http://jnm.snmjournals.org/content/61/supplement_1/461.abstract AB 461Background: Progressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder characterized by tau pathology in neurons and glial cells. As the next generation PET imaging agent, [18F]-APN-1607 ([18F]-PM-PBB3) was designed for capturing pathological tau aggregates in diverse neurodegenerative disorders. This work explored the usefulness of [18F]-APN-1607 in assessing characteristic distributions of tau pathologies and their association with clinical symptoms of living progressive supranuclear palsy (PSP) patients. METHODS: We assessed 18 PSP patients and 10 age-matched healthy control subjects. Both cohorts underwent clinical scoring, MR scans, and [18F]-APN-1607 PET/CT scans. The tosylate precursor used for the synthesis of [18F]-APN-1607 was provided by APRINOIA Therapeutics (Suzhou, China) and the synthesis was prepared in Huashan hospital (Shanghai, China). PET images were spatially normalized to Montreal Neurological Institute template space. Standard uptake value ratios (SUVRs) were calculated using AAL3 (Automated Anatomical Labeling atlas) volumes of interest (VOIs). All VOIs were referenced to a subsection of cerebellar gray matter (cere-crus) as well as a parametrically derived white matter-based reference region (parametric estimate of reference signal intensity [PERSI]). T test and correlation analyses were used to explore its performance. RESULTS: There were significant differences in binding potential for [18F]-APN-1607 between PSP patients and healthy control subjects. PSP patients exhibited greater radioligand retention than healthy control subjects in multiple brain regions, including occipital lobe (0.991±0.038), caudate (0.832±0.078), putamen(1.271±0.152), pallidum (1.561±0.171), raphe nucleus(1.683±0.312), and substantia nigra (1.355±0.186). Conclusions: This study demonstrated significant uptake discrimination of [18F]-APN-1607 between PSP and HC subjects in occipital lobe, caudate, putamen, pallidum, raphe nucleus, and substantia nigra, which may reflect neuropathology. We are recruiting more patients in a follow-up study to explore association between measures of tau pathology and clinical assessment in PSP cohort.